TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

MLA

Loriot, Y., et al. “TROPHY-U-01, a Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing after Platinum-Based Chemotherapy and Checkpoint Inhibitors: Updated Safety and Efficacy Outcomes.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 35, no. 4, Apr. 2024, pp. 392–401. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.01.002.

APA

Loriot, Y., Petrylak, D. P., Rezazadeh Kalebasty, A., Fléchon, A., Jain, R. K., Gupta, S., Bupathi, M., Beuzeboc, P., Palmbos, P., Balar, A. V., Kyriakopoulos, C. E., Pouessel, D., Sternberg, C. N., Tonelli, J., Sierecki, M., Zhou, H., Grivas, P., Barthélémy, P., & Tagawa, S. T. (2024). TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 35(4), 392–401. https://doi.org/10.1016/j.annonc.2024.01.002

Chicago

Loriot, Y, D P Petrylak, A Rezazadeh Kalebasty, A Fléchon, R K Jain, S Gupta, M Bupathi, et al. 2024. “TROPHY-U-01, a Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing after Platinum-Based Chemotherapy and Checkpoint Inhibitors: Updated Safety and Efficacy Outcomes.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 35 (4): 392–401. doi:10.1016/j.annonc.2024.01.002.